This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for continuing Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and Visionary Health Concepts.  MEC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Collaborative designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding the accreditation of this activity, please contact Medical Education Collaborative at (303) 420-3252.

Upon completion of this educational activity, participants should be able to:   

• Evaluate reasons for determining tropism at various time points

• Discuss clinical protocol for determining tropism in the undetectable patient and considerations of when to re-test

The purpose of this activity is to assist providers in the consideration of recent data related to ART agents in various scenarios and in weighing therapeutic trade-offs when using regimens that may contain one or more partially active agents.

The program is intended for physicians and other healthcare providers treating HIV-positive patients, especially those who are seeking clinically-relevant and comprehensive information on viral resistance. Participants should have basic scientific knowledge and understanding of HIV disease and its treatment.

This activity is joint sponsored by Visionary Health Concepts and Medical Education Collaborative (MEC).  MEC is a non-profit organization

 that has been certifying quality educational activities since 1988.

Disclaimer: The opinions expressed in this educational activity are those of the faculty and do not reflect the views of Medical Education Collaborative and Visionary Health Concepts. This educational activity may discuss off-label and/or investigational uses and dosages for therapeutic products/procedures that have not been approved by the United States Food and Drug Administration (FDA). Medical Education Collaborative and Visionary Health Concepts do not recommend the use of any product/procedure outside of the labeled indications. A qualified health care professional should be consulted before using any therapeutic product/procedure discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.  Please refer to the official prescribing information for each product/procedures for approved indication, contraindications, and warnings.

This activity was made possible by an unrestricted educational grant from Tibotec Therapeutics.

Medical Education Collaborative adheres to ACCME Essential Areas and Policies, including the Standards for Commercial Support regarding industry support of continuing medical education   In order to resolve any identified conflicts of interest, disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships, as well as the discussion of unlabeled or unapproved use of any drug, device, or procedure by the faculty, are made known below.

CME Chairperson

Jonathan Schapiro, MD

Director HIV/AIDS, National Hemophelia Center, Israel

Adjunct Clinical Assistant Professor of Medicine (VCF)

Stanford University School of Medicine, Stanford, CA

  Jonathan Schapiro, MD has the following relationships to disclose: research support, honorarium or consulting fees from   

  the following: Abbott, Ambrillia, Bayer, Bristol Myers Squibb, Gilead, Merck, Monogram Biosciences, Pfizer, Roche,

  Siemens, and Tibotec Therapeutics.

Editors

Jacob Lalezari, MD

Medical Director

Quest Clinical Research

Assistant Clinical Professor of Medicine

University of California, San Francisco

Jacob Lalezari, MD has the following relationships to disclose: clinical research support from Boehringer Ingelheim,

GlaxoSmithKline, Koronis, Medarex, Merck, Panacos, Pfizer, Pharmasset, Progenics, Roche and Tibotec.

Roger Paredes, MD

Senior Researcher

IrsiCaixa Retrovirology Laboratory

Catalonia, Spain 

Roger Paredes, MD has the following relationships to disclose:  research support from Merck, Sharp & Dohme and Pfizer.

Editor-in-Chief, Writer

               Lillian Thiemann

               President

               Visionary Health Concepts

               Lillian Thiemann has no relationships to disclose.       

Accredited Provider

          Employees of Medical Education Collaborative, the accredited provider for this activity, have

          disclosed that they have no significant financial relationships. 

Read the target audience, objectives, faculty disclosures and accreditation statements, then read the ResistanceWATCH News online. Upon reading all the content, complete the CME Post Test, Course Evaluation and Credit Application online to receive your certificate. You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate.

Medical Education Collaborative (MEC) protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. MEC and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

Medical Education Collaborative (MEC) and Visionary Health Concepts maintain physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Release Date: December 17, 2008 Expiration Date: December 17, 2009 Visionary Health Concepts.  All Rights Reserved.  Permission for accreditation use granted to Medical Education Collaborative (MEC).

 VHConcepts requires version 4.x browsers or higher from Microsoft or Netscape.